To update treatment options and considerations for castration-resistant prostate cancer with specific attention to sequencing of agents based on available evidence and treatment rationale.
The newest research developments over the last several years include multicenter studies that address the sequencing of therapies to improve the treatment of metastatic castration-resistant prostate cancer. Chemotherapy agents, as well as androgen receptor antagonists, are evolving, and there are new tests available to define which patients are more likely to benefit. In addition, there have been some additional trials looking into the safety and efficacy of combination treatment and new therapies. There are multiple factors that should be considered to determine the sequence and/or combinations of therapies for metastatic castration-resistant prostate cancer that can improve quality of life and survival. Promising novel agents in combination with personalized medicine will likely continue to improve treatment of these patients.
Current urology reports. 2018 Jul 20*** epublish ***
Sarah Bennett Starosta, Stephen J Savage
Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas St. CSB 644, Charleston, SC, 29425, USA., Department of Urology, Medical University of South Carolina, 96 Jonathan Lucas St. CSB 644, Charleston, SC, 29425, USA. .